TITLE: Left Atrial Appendage Occlusion: Economic Impact and Existing HTA Recommendations
|
|
- Ezra Daniel
- 5 years ago
- Views:
Transcription
1 TITLE: Left Atrial Appendage Occlusion: Economic Impact and Existing HTA Recommendations DATE: 29 September 2010 CONTEXT AND POLICY ISSUES: Atrial fibrillation (AF) is the irregular, rapid beating of the atria of the heart and is the most common cardiac arrhythmia. 1 Patients with AF have an elevated risk of stroke, which is a leading cause of death and disability among patients with the condition. 1 The elevated risk of stroke in AF relates to a predisposition to inefficient blood flow. Stagnation of blood flow in the left atrium can lead to thrombus formation, which increases the risk of embolic stroke. 1,2 The left atrial appendage (LAA) is a small, long tubular structure branching from the left atrial cavity. 3 Because of its anatomy, the efficiency of blood flow in the LAA is reduced. In patients with AF, over 90% of atrial thrombi originate in the LAA. 4,5 A number of drugs are in use or clinical trials for stroke prevention in atrial fibrillation, including anticoagulants, antiplatelet agents, thrombin inhibitors and Factor Xa inhibitors. 5 The anticoagulant warfarin is often used for stroke prevention in patients with AF at high-risk for stroke who have no contraindications. Warfarin has consistently been shown to reduce the risk of stroke in patients with AF by over 60% compared to no treatment, and by 30% to 40% compared to low-dose aspirin. 5,6 However, warfarin use has some disadvantages including numerous food and drug interactions, the need for frequent monitoring, and the risk of bleeding complications. Because of this, alternative therapies for stroke prevention have been sought. One alternative that has been explored is the occlusion of the LAA to prevent thrombi escape. 1 As surgical occlusion or removal of the LAA is invasive and limited to patients undergoing openheart surgery, devices for percutaneous occlusion of the LAA have been developed. 1,4,5 The first such device developed as an alternative to surgical occlusion was the percutaneous left atrial appendage transcatheter occlusion (PLAATO) system, which showed a reduction in stroke rate in clinical trials but was discontinued due to economic reasons. 1,4,5 The Watchman device is a newer device available for LAA occlusion and was evaluated in a large prospective, randomized controlled trial (PROTECT-AF) 7 which demonstrated its non-inferiority to chronic warfarin for stroke prevention in AF patients. 8 Though not yet licensed by Health Canada, patients unable to Disclaimer: The Health Technology Inquiry Service (HTIS) is an information service for those involved in planning and providing health care in Canada. HTIS responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources and a summary of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. HTIS responses should be considered along with other types of information and health care considerations. The information included in this response is not intended to replace professional medical advice, nor should it be construed as a recommendation for or against the use of a particular health technology. Readers are also cautioned that a lack of good quality evidence does not necessarily mean a lack of effectiveness particularly in the case of new and emerging health technologies, for which little information can be found, but which may in future prove to be effective. While CADTH has taken care in the preparation of the report to ensure that its contents are accurate, complete and up to date, CADTH does not make any guarantee to that effect. CADTH is not liable for any loss or damages resulting from use of the information in the report. Copyright: This report contains CADTH copyright material. It may be copied and used for non-commercial purposes, provided that attribution is given to CADTH. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners own terms and conditions.
2 take warfarin can get the Watchman through a compassionate use process. Another device, the Amplatzer Septal Occluder (ASO), has been used for LAA occlusion and is licensed for use in Canada but was not designed for this purpose. 4 This report examines the evidence of the cost-effectiveness of percutaneous occlusion of the LAA in patients with AF who are at elevated risk for stroke. RESEARCH QUESTIONS: 1. What is the cost-effectiveness of percutaneous occlusion of the left atrial appendage for patients with non-valvular atrial fibrillation at elevated risk for stroke? 2. What are the evidence-based recommendations that considered cost-effectiveness of percutaneous occlusion of the left atrial appendage for patients with non-valvular atrial fibrillation at elevated risk for stroke? METHODS: A limited literature search was conducted on key health technology assessment resources, including Ovid MEDLINE (1950 to August Week ), PubMed, The Cochrane Library (Issue 8, 2010), University of York Centre for Reviews and Dissemination (CRD) databases, ECRI (Health Devices Gold), EuroScan, international health technology agencies, and a focused Internet search. The search was limited to English language, with no time limit for articles publication dates. No filters were applied to limit the retrieval by study type. SUMMARY OF FINDINGS: One publication 3 was identified that included a cost analysis of LAA occlusion for stroke prevention. No relevant guidelines were identified. Economic evaluations In 2010, the North East Treatment Advisory Group performed a cost analysis of the use of the Watchman device for LAA occlusion and stroke prevention compared to low-dose aspirin. 3 Costing was performed from the perspective of the National Health Service (NHS), but was not specific to patients with AF. Costs were calculated in pounds ( ), but it was unclear what year was used for costing. Using figures for the United Kingdom (UK) health care system, the estimated cost of implanting a Watchman device without complications was 11,380. This estimate was derived from a device cost of 5,280 (including value added tax), procedure cost of 5,951 (based on NHS payment-by-results billing codes) and the cost of post-procedural drugs. Using a calculated number needed to treat (NNT) of 100, based on a meta-analysis of antithrombotic therapy for stroke prevention 9 and results of the PROTECT-AF trial, 8 the estimated cost to prevent one stroke compared to aspirin alone was 1.14 million annually. An NNT of 100 indicates that, compared to treatment with aspirin alone, 100 patients would be required to receive the device to prevent one ischemic stroke. Assuming a 10-year survival Left Atrial Appendage Occlusion for Stroke Prevention 2
3 period, the authors calculated a cost of 114,000 per stroke prevented. The average lifetime cost of a stroke was estimated to be 18,000, with the lifetime cost of a severe stroke, which tends to have higher levels of residual disability, estimated at 50,000, less than one-half of the Watchman procedure cost. Because the cost estimates are dependent on expected survival rates and residual disability following a stroke, the authors state that it is difficult to determine whether a Watchman device for stroke prevention meets the conventional criteria for cost-effectiveness. The authors concluded that the benefits of stroke reduction by a Watchman device may be greater in patients with a high baseline risk. Given the demographics of their patient population, with an annual risk of ischemic stroke of 4%, the authors concluded that the majority of patients would derive no benefit from the Watchman device. This study is limited by the underlying assumptions of the analysis, particularly the assumption of a 10-year survival period, which may be optimistic given a predominantly male patient population with a mean age of 72. Furthermore, estimates of stroke risk were not specifically based on patients with non-valvular AF. The analysis is sensitive to both the survival rate and the estimated cost of a stroke, which depends on residual disability, but no sensitivity analysis was done. Adverse event rates were not considered, though they may affect treatment costs, nor were pre- and post-operative appointment costs. The cost analysis was carried out relative to low-dose aspirin, not warfarin which may be the preferred treatment for patients with higher risk of stroke. 5 Aspirin is generally indicated for patients with low to moderate risk of stroke. 5 Finally, cost analysis was done based on costs in the UK and may not be generalizable to the Canadian health care system. Limitations One cost analysis was identified, comparing the Watchman device for LAA occlusion plus lowdose aspirin to low-dose aspirin alone for stroke prevention. This analysis was based on estimates from the UK and may not generalize to a Canadian context. The available analysis was done comparing one particular device for LAA occlusion (Watchman) and one drug regimen (low-dose aspirin) and, therefore, may not be generalizable to other occlusion devices, such as PLAATO or ASO devices, or other drugs, such as warfarin. CONCLUSIONS AND IMPLICATIONS FOR DECISION OR POLICY MAKING: One UK-based cost analysis was identified. This analysis indicated that the Watchman device for stroke prevention by LAA occlusion was more costly per stroke prevented than low-dose aspirin. However due to the limitations of this analysis and the lack of additional economic evidence, it is difficult to draw firm conclusions on the cost-effectiveness of LAA occlusion for stroke prevention in patients with non-valvular AF. No evidence-based guidelines or recommendations that considered cost-effectiveness were identified, nor were any cost-effectiveness evaluations. Left Atrial Appendage Occlusion for Stroke Prevention 3
4 PREPARED BY: Health Technology Inquiry Service Tel: Left Atrial Appendage Occlusion for Stroke Prevention 4
5 REFERENCES: 1. Singh IM, Holmes DR, Jr. Left atrial appendage closure. Curr Cardiol Rep Sep;12(5): El-Chami MF, Hoffman M, Lerakis S. Sealing the left atrial appendage: ready for prime time? Am J Med Sci May;333(5): Horsley W. Left atrial appendage occlusion with the Watchman TM device for stroke prevention in patients with atrial fibrillation [Internet]. Newcastle upon Tyne (UK): North East Treatment Advisory Group; 2010 Jul. [cited 2010 Sep 3]. Available from: %20Watchman%20device%20-July% pdf 4. Gorodnitskiy A, Lucariello RJ, Aizer A, Coppola JT. A novel approach to left atrial appendage exclusion: the WATCHMAN device. Cardiol Rev Sep;18(5): Savelieva I, Bajpai A, Camm AJ. Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices. Ann Med. 2007;39(5): Hankey GJ. Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs? Curr Opin Neurol Feb;23(1): Fountain RB, Holmes DR, Chandrasekaran K, Packer D, Asirvatham S, Van Tassel R, et al. The PROTECT AF (WATCHMAN left atrial appendage system for embolic PROTECTion in patients with Atrial Fibrillation) trial. Am Heart J May;151(5): Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet Aug 15;374(9689): Hart RG, Benavente O, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med Oct 5;131(7): Left Atrial Appendage Occlusion for Stroke Prevention 5
TITLE: Dose of Electrical Current for Biphasic Defibrillators for Synchronous Cardioversion in Patients with Tachyarrhythmia: Guidelines
TITLE: Dose of Electrical Current for Biphasic Defibrillators for Synchronous Cardioversion in Patients with Tachyarrhythmia: Guidelines DATE: 5 May 2009 RESEARCH QUESTION: What recommendations exist for
More informationCADTH Therapeutic Review
Canadian Agency for Drugs and Technologies in Health Agence canadienne des médicaments et des technologies de la santé CADTH Therapeutic Review August 2012 Volume 1, Issue 1A Antithrombotic Therapy for
More informationDATE: 17 July 2012 CONTEXT AND POLICY ISSUES
TITLE: Sterile Pre-filled Saline Syringes for Acute Care Patients: A Review of Clinical Evidence, Cost-effectiveness, Evidence-based Guidelines, and Safety DATE: 17 July 2012 CONTEXT AND POLICY ISSUES
More informationTITLE: Use of Bupropion in Patients with Depression and the Associated Risk of Seizures: Safety
TITLE: Use of Bupropion in Patients with Depression and the Associated Risk of Seizures: Safety DATE: 1 April 2010 CONTEXT AND POLICY ISSUES: The prevalence of epilepsy ranges from 0.5% to 1%, 1,2 and
More informationTITLE: Closed Catheter Systems for Prevention of Urinary Tract Infections: A Review of the Clinical Effectiveness
TITLE: Closed Catheter Systems for Prevention of Urinary Tract Infections: A Review of the Clinical Effectiveness DATE: 24 November 2008 CONTEXT AND POLICY ISSUES: Urinary tract infections (UTI) are the
More informationTITLE: Discontinuation of Benzodiazepines and Other Sedative-Hypnotic Sleep Medication in Hospitalized Patients: Clinical Evidence and Guidelines
TITLE: Discontinuation of Benzodiazepines and Other Sedative-Hypnotic Sleep Medication in Hospitalized Patients: Clinical Evidence and Guidelines DATE: 25 September 2015 RESEARCH QUESTIONS 1. What is the
More informationDATE: 04 April 2012 CONTEXT AND POLICY ISSUES
TITLE: Procedure Site Bleeding Complications Following Percutaneous Coronary Interventions or Angioplasty: A Review of Clinical Evidence and Guidelines DATE: 04 April 2012 CONTEXT AND POLICY ISSUES Percutaneous
More informationTITLE: Hyperbaric Oxygen Therapy for Adults with Mental Illness: A Review of the Clinical Effectiveness
TITLE: Hyperbaric Oxygen Therapy for Adults with Mental Illness: A Review of the Clinical Effectiveness DATE: 27 August 2014 CONTEXT AND POLICY ISSUES Mental illness, including major depressive episode,
More informationTITLE: Probenecid Dosing When Given with Cefazolin: Guidelines and Clinical Effectiveness
TITLE: Probenecid Dosing When Given with Cefazolin: Guidelines and Clinical Effectiveness DATE: 21 November 2008 RESEARCH QUESTIONS: 1. What is the evidence for the clinical effectiveness of the 1g dose
More informationDATE: 09 December 2009 CONTEXT AND POLICY ISSUES:
TITLE: Tiotropium Compared with Ipratropium for Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease: A Review of the Clinical Effectiveness DATE: 09 December 2009 CONTEXT AND POLICY
More informationOcclusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France
Occlusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France LAA Occlusion Is there a real future? Background Protect AF Trial Other Studies CAP, ASAP, Prevail Left Atrial Appendage
More informationTitle: Shortened Dental Arch and Restorative Therapies: Evidence for Functional Dentition
Title: Shortened Dental Arch and Restorative Therapies: Evidence for Functional Dentition Date: 15 May 2008 Context and policy issues: For patients who lose teeth due to various reasons, a fundamental
More informationTITLE: Naltrexone for the Treatment of Alcohol Dependence in Individuals with Co- Dependencies: A Review of the Clinical Effectiveness
TITLE: Naltrexone for the Treatment of Alcohol Dependence in Individuals with Co- Dependencies: A Review of the Clinical Effectiveness DATE: 08 October 2009 CONTEXT AND POLICY ISSUES: Poly-drug abuse is
More informationTITLE: Patient-Controlled Analgesia for Acute Injury Transfers: A Review of the Clinical Effectiveness, Safety, and Guidelines
TITLE: Patient-Controlled Analgesia for Acute Injury Transfers: A Review of the Clinical Effectiveness, Safety, and Guidelines DATE: 11 August 2014 CONTEXT AND POLICY ISSUES Patient-controlled analgesia
More informationTitle: Re-using the Canister Portion of Metered Dose Inhalers in a Hospital Setting: Clinical Review of Safety, Cost-Effectiveness and Guidelines
Title: Re-using the Canister Portion of Metered Dose Inhalers in a Hospital Setting: Clinical Review of Safety, Cost-Effectiveness and Guidelines Date: 16 June 2008 Context and policy issues: A metered
More informationTITLE: Vacuum Boards for Spinal Motion Restriction: Clinical Effectiveness
TITLE: Vacuum Boards for Spinal Motion Restriction: Clinical Effectiveness DATE: 14 October 2008 RESEARCH QUESTION: What are the clinical benefits and harms of using vacuum boards for spinal motion restriction?
More informationTitle: Scoop Stretcher for Restriction of Spinal Motion: Clinical Effectiveness
Title: Scoop Stretcher for Restriction of Spinal Motion: Clinical Effectiveness Date: 28 May 2008 Research question: What is the evidence for the clinical effectiveness of a scoop stretcher to restrict
More informationCADTH RAPID RESPONSE REPORT: REFERENCE LIST Side Effect Free Chemotherapy for the Treatment of Cancer: Clinical Effectiveness
CADTH RAPID RESPONSE REPORT: REFERENCE LIST Side Effect Free Chemotherapy for the Treatment of Cancer: Clinical Effectiveness Service Line: Rapid Response Service Version: 1.0 Publication Date: August
More informationDate: 23 June Context and policy issues:
Title: Basiliximab for Immunosuppression During a Calcineurin Inhibitor Holiday in Renal Transplant Patients with Acute Renal Dysfunction: Guidelines for Use and a Clinical and Cost-Effectiveness Review
More informationTitle: Parenteral Iron Therapy for Anemia: A Clinical and Cost-Effectiveness Review
Title: Parenteral Iron Therapy for Anemia: A Clinical and Cost-Effectiveness Review Date: 14 February 2008 Context and policy issues: Anemia is a complication of chronic diseases and commonly occurs in
More informationLeft Atrial Appendage Closure for Atrial Fibrillation 2015 UPDATE
Left Atrial Appendage Closure for Atrial Fibrillation 2015 UPDATE Adam Greenbaum, MD NCVH Detroit 2015-09-12 Disclosures Former proctor: SentreHEART Discussion may include the use of non-fda approved devices
More informationTITLE: Hyperbaric Oxygen Therapy for Autism: A Review of the Clinical and Cost- Effectiveness
TITLE: Hyperbaric Oxygen Therapy for Autism: A Review of the Clinical and Cost- Effectiveness DATE: 19 November 2009 CONTEXT AND POLICY ISSUES: Autism is a pervasive developmental disorder characterized
More informationTitle: Elective Endovascular Abdominal Aortic Aneurism Repair versus Open Surgery: A Clinical and Cost Effectiveness Review
Title: Elective Endovascular Abdominal Aortic Aneurism Repair versus Open Surgery: A Clinical and Cost Effectiveness Review Date: 07 April 2008 Context and policy issues: Abdominal aortic aneurism (AAA)
More informationTITLE: Type of Thermometer for Inpatients: Clinical-Effectiveness and Guidelines
TITLE: Type of Thermometer for Inpatients: Clinical-Effectiveness and Guidelines DATE: 28 May 2009 RESEARCH QUESTIONS: 1. What is the clinical-effectiveness of tympanic, temporal, oral, and rectal thermometers
More informationTITLE: Delivery of Electroconvulsive Therapy in Non-Hospital Settings: A Review of the Safety and Guidelines
TITLE: Delivery of Electroconvulsive Therapy in Non-Hospital Settings: A Review of the Safety and Guidelines DATE: 08 May 2014 CONTEXT AND POLICY ISSUES Electroconvulsive therapy (ECT) is a treatment that
More informationTITLE: Montelukast for Sleep Apnea: A Review of the Clinical Effectiveness, Cost Effectiveness, and Guidelines
TITLE: Montelukast for Sleep Apnea: A Review of the Clinical Effectiveness, Cost Effectiveness, and Guidelines DATE: 17 January 2014 CONTEXT AND POLICY ISSUES Obstructive sleep apnea (OSA) is a common
More informationPatients selection criteria for LAA occlusion. Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine
Patients selection criteria for LAA occlusion Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine Atrial Fibrillation The most common cardiac arrhythmia. Confers
More informationLeft atrial appendage occlusion
Kardiologie Left atrial appendage occlusion Mischa Kühne Kardiolunch, 10.9.2015 Overall stroke rate 5% per year CHA 2 DS 2 VASC score Most AF patients need protection from stroke ESC guidelines AF, 2010/2012
More informationA PATIENT S GUIDE TO THE LEFT ATRIAL APPENDAGE CLOSURE. Reducing the risk of stroke in atrial fibrillation
A PATIENT S GUIDE TO THE LEFT ATRIAL APPENDAGE CLOSURE Reducing the risk of stroke in atrial fibrillation TABLE OF CONTENTS IMPORTANT Please Note: Information provided by Boston Scientific Corporation
More informationTITLE: Memantine in Combination with Cholinesterase Inhibitors for Alzheimer s Disease: Clinical Effectiveness
TITLE: Memantine in Combination with Cholinesterase Inhibitors for Alzheimer s Disease: Clinical Effectiveness DATE: 30 October 2008 RESEARCH QUESTION: What is the evidence for using memantine in combination
More informationTITLE: Critical Incident Stress Debriefing for First Responders: A Review of the Clinical Benefit and Harm
TITLE: Critical Incident Stress Debriefing for First Responders: A Review of the Clinical Benefit and Harm DATE: 12 February 2010 CONTEXT AND POLICY ISSUES: Critical incident stress debriefing (CISD) is
More informationTHINK OUTSIDE THE PILLBOX
WATCHMAN : A CLINICALLY PROVEN AND SAFE THERAPY FOR YOUR NVAF PATIENTS WATCHMAN reduces the risk of stroke in NVAF patients as effectively as warfarin WATCHMAN also reduces the long-term risk of bleeding
More informationAppendage Closure. Jason Rogers, MD. Director, Interventional Cardiology UC Davis Medical Center Sacramento, California
Appendage Closure Jason Rogers, MD Director, Interventional Cardiology UC Davis Medical Center Sacramento, California Left Atrium: Atrial Fibrillation Left Atrial Appendage Left Atrium Incidence of Atrial
More informationContinuing Cardiology Education
Continuing Cardiology Education REVIEW ARTICLE Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation: indications diversity and future perspectives A. Tzikas 1 & T.
More informationClinical Data Summary & Discussion Of the Ultraseal Left Atrial Appendage (LAA) Closure Device
Clinical Data Summary & Discussion Of the Ultraseal Left Atrial Appendage (LAA) Closure Device The clinical data used to support the CE marking of the Ultraseal LAA Closure device comes from three sources.
More informationNCVH Birmingham 2013 August 24, Michael S. Bailey, MD Birmingham Heart Clinic
NCVH Birmingham 2013 August 24, 2013 Michael S. Bailey, MD Birmingham Heart Clinic NCVH Birmingham 2015 August 29, 2015 Michael S. Bailey, MD Birmingham Heart Clinic Left Atrial Anatomy Part of a larger
More informationMedical Policy Manual. Topic: Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation. Date of Origin: December 2011
Medical Policy Manual Topic: Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Date of Origin: December 2011 Section: Medicine Last Reviewed Date: October 2013 Policy No:
More informationCommercial Products Percutaneous left atrial appendage closure is considered medically necessary when the criteria above is met.
Medical Coverage Policy Percutaneous Left Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation EFFECTIVE DATE: 07 01 2016 POLICY LAST UPDATED: 09 04 2018 OVERVIEW Stroke prevention
More informationTITLE: Australian Sheepskins for the Management of Pressure Ulcers: A Review of the Clinical-Effectiveness, Cost-Effectiveness, and Guidelines
TITLE: Australian Sheepskins for the Management of Pressure Ulcers: A Review of the Clinical-Effectiveness, Cost-Effectiveness, and Guidelines DATE: 21 July 2009 CONTEXT AND POLICY ISSUES: Pressure ulcers,
More informationWatchman. Left Atrial Appendage Closure Device. Uniquely engineered for the LAA 1-3 with proven safety and longterm efficacy. 4-8
TM Watchman Left Atrial Appendage Closure Device PROOF OFLEADERSHIP Uniquely engineered for the LAA 1-3 with proven safety and longterm efficacy. 4-8 Patients with AF have a 5x increased risk of stroke.
More informationLeft atrial appendage closure for thromboembolism prevention in patients with atrial fibrillation: advances and perspectives
Review Article Left atrial appendage closure for thromboembolism prevention in patients with atrial fibrillation: advances and perspectives Bin Kong 1,2, Yu Liu 1,2, He Huang 1,2, Hong Jiang 1,2, Congxin
More informationRole of cardiac imaging for catheterbased left atrial appendage closure
Role of cardiac imaging for catheterbased left atrial appendage closure Ana G. Almeida, MD, PhD Cardiology University Hospital Santa Maria, Lisbon Ana G. Almeida, MD, PhD, FESC University Hospital Santa
More informationTITLE: Dental Loupes for Dental Procedures: A Review of the Clinical and Cost- Effectiveness
TITLE: Dental Loupes for Dental Procedures: A Review of the Clinical and Cost- Effectiveness DATE: 08 October 2008 CONTEXT AND POLICY ISSUES: The use of magnification in dentistry is expanding rapidly.
More informationThis report will provide a review on the comparative clinical effectiveness and safety between intranasal triamcinolone and beclomethasone.
TITLE: Intranasal Triamcinolone versus Intranasal Beclomethasone for Acute and Chronic Sinus Inflammation: A Review of Comparative Clinical Effectiveness and Safety DATE: 29 January 2013 CONTEXT AND POLICY
More informationLeft Atrial Appendage Occlusion: Shutting Out Embolic Disease Without Anticoagulation
Left Atrial Appendage Occlusion: Shutting Out Embolic Disease Without Anticoagulation Zoltan G. Turi, M.D. Rutgers Robert Wood Johnson Medical School New Brunswick, NJ Disclosure Information Zoltan G.
More informationTITLE: Chiropractic Interventions for Acute or Chronic Lower Back Pain in Adults: A Review of the Clinical and Cost-Effectiveness
TITLE: Chiropractic Interventions for Acute or Chronic Lower Back Pain in Adults: A Review of the Clinical and Cost-Effectiveness DATE: 10 February 2009 CONTEXT AND POLICY ISSUES: Low back pain (LBP) is
More informationTITLE: Immediate Osseointegrated Implants for Cancer Patients: A Review of Clinical and Cost-Effectiveness
TITLE: Immediate Osseointegrated Implants for Cancer Patients: A Review of Clinical and Cost-Effectiveness DATE: 13 January 2015 CONTEXT AND POLICY ISSUES According to the World health Organization, the
More informationIndex. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Acute ischemic stroke TOAST classification of, 270 Acute myocardial infarction (AMI) cardioembolic stroke following, 207 208 noncardioembolic
More informationTITLE: Computed Tomography: A Review of the Risk of Cancer Associated with Radiation Exposure
TITLE: Computed Tomography: A Review of the Risk of Cancer Associated with Radiation Exposure DATE: 18 August 2009 CONTEXT AND POLICY ISSUES: Health care professionals order diagnostic imaging for their
More informationLeft Atrial Appendage Occlusion in the Era of Novel Anticoagulants
Left Atrial Appendage Occlusion in the Era of Novel Anticoagulants Saibal Kar, MD, FACC, FSCAI Professor of Medicine Director of Interventional Cardiac Research Heart Institute, Cedars-Sinai Medical Center,
More informationLeft Atrial Appendage Occlusion
Left Atrial Appendage Occlusion A new strategy to prevent stroke in atrial fibrillation Ashok Talreja MD and Arijit Chanda MD VHVI symposium 24th February 2018 Outline of presentation 1. Risk of stroke
More informationLeft Atrial Appendage Closure: Moving Beyond Blood Thinners to Prevent Stroke in Atrial Fibrillation October 29, 2016
Left Atrial Appendage Closure: Moving Beyond Blood Thinners to Prevent Stroke in Atrial Fibrillation October 29, 2016 Jesse Jorgensen, MD, FACC Director, Cardiac Cath Lab, Greenville Health System Disclosures
More informationTitle: Ultrasound for Breast Cancer Screening: Clinical Effectiveness. Date: 4 January Context and policy issues:
Title: Ultrasound for Breast Cancer Screening: Clinical Effectiveness Date: 4 January 2008 Context and policy issues: It is estimated that 22,300 women will be diagnosed with breast cancer and approximately
More informationPage 1. Current Trends in the Management of Atrial Fibrillation: Left Atrial Appendage Occlusion. Atrial fibrillation: Scope of the problem
Current Trends in the Management of Atrial Fibrillation: Left Atrial Appendage Occlusion Benjamin A. D Souza, MD, FACC, FHRS Assistant Professor of Clinical Medicine Penn Presbyterian Medical Center Cardiac
More informationLeft Atrial Appendage Closure Devices. Atrial Fibrillation 10/11/2017
Left Atrial Appendage Closure Devices Emile Daoud, MD Chief, Cardiac Electrophysiology Wexner Medical Center, The Ohio State University Atrial Fibrillation 1 Adjusted Annual Stroke Risk Using CHA 2 DS
More informationLeft atrial appendage closure with the Amplatzer Cardiac Plug: Rationale for a higher degree of device oversizing at implantation
ORIGINAL ARTICLE Cardiology Journal 2015, Vol. 22, No. 2, 201 205 DOI: 10.5603/CJ.a2014.0063 Copyright 2015 Via Medica ISSN 1897 5593 Left atrial appendage closure with the Amplatzer Cardiac Plug: Rationale
More information[N] = No product variation, policy applies as stated [Y] = Standard product coverage varies from application of this policy, see below
Original Issue Date (Created): July 26, 2011 Most Recent Review Date (Revised): November 26, 2013 Effective Date: February 1, 2014 I. POLICY The use of percutaneous left-atrial appendage closure devices
More informationPERCUTANEOUS STRUCTURAL UPDATES TAVR WATCHMAN(LEFT ATRIAL APPENDAGE OCCLUDERS) MITRACLIP PARAVALVULAR LEAK REPAIRS ASD/PFO CLOSURES VALVULOPLASTIES
PERCUTANEOUS STRUCTURAL UPDATES TAVR WATCHMAN(LEFT ATRIAL APPENDAGE OCCLUDERS) MITRACLIP PARAVALVULAR LEAK REPAIRS ASD/PFO CLOSURES VALVULOPLASTIES Dr.Vinny K.Ram No disclosures TAVR 1 Lesson number 1:
More informationModern aspects in multidisciplinary thromboembolic prophylaxis. AMPLATZER Left Atrial Appendage data update
Modern aspects in multidisciplinary thromboembolic prophylaxis AMPLATZER Left Atrial Appendage data update Igal Moarof, MD Interventional Cardiology Kantonsspital Aarau Potential conflicts of interest
More informationIntroduction EP WIRE. ... Keywords
Europace (217), 1 6 doi:1.3/europace/eux254 EP WIRE Left atrial appendage occluder implantation in Europe: indications and anticoagulation post-implantation. Results of the European Heart Rhythm Association
More informationDevices to Protect Against Stroke in Atrial Fibrillation
Devices to Protect Against Stroke in Atrial Fibrillation Jonathan C. Hsu, MD, MAS Associate Clinical Professor Division of Cardiology, Section of Cardiac Electrophysiology June 2, 2018 Disclosures Honoraria
More informationWatchman a Stroke Prevention Technology for Patients with Atrial Fibrillation
Watchman a Stroke Prevention Technology for Patients with Atrial Fibrillation Scripps hospital,la Jolla, CA Atrial fibrillation is a major source of cardiogenic embolic related stroke 500,000 strokes per
More informationTITLE: Acetylsalicylic Acid for Venous Thromboembolism Prophylaxis: A Review of Clinical Evidence, Benefits and Harms
TITLE: Acetylsalicylic Acid for Venous Thromboembolism Prophylaxis: A Review of Clinical Evidence, Benefits and Harms DATE: 23 August 2011 CONTEXT AND POLICY ISSUES: Thromboembolism occurs when a blood
More informationAtrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases?
Atrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases? Nicolas Lellouche Fédération de Cardiologie Hôpital Henri Mondor Créteil Disclosure Statement of Financial Interest I currently
More informationAtrial fibrillation (AF) affects approximately 33 million
Emerging Options for Anticoagulation in LAA Closure Managing anticoagulation and antiplatelet therapy in patients undergoing percutaneous left atrial appendage closure with the Watchman device. BY JESSICA
More informationUse this pitch template if your hospital would like to promote a milestone implant number of the WATCHMAN device at your facility.
Table of Contents PITCH ONE: First to Offer WATCHMAN in your area If you are the first to offer the WATCHMAN Left Atrial Appendage Closure (LAAC) Device in your area, use this pitch note to reach out to
More informationLeft Atrial Appendage Occlusion: A Valid Option to Anticoagulation for Long-term Prevention of Stroke Saibal Kar, MD
Left Atrial Appendage Occlusion: A Valid Option to Anticoagulation for Long-term Prevention of Stroke Saibal Kar, MD Director of Interventional Cardiac Research Cedars Sinai Medical Center Disclosure Statement
More informationDevice-associated thrombus after percutaneous left atrial appendage closure: a case report and literature review
CSE REPORT Iwona Świątkiewicz, Marek Woźnicki, dam Sukiennik, Jacek Kubica Department of Cardiology and Internal Medicine, Ludwik Rydygier Collegium Medicum, Nicolaus Copernicus University, ydgoszcz, Poland
More informationMEDICAL POLICY SUBJECT: PERCUTANEOUS LEFT ATRIAL APPENDAGE CLOSURE DEVICES EFFECTIVE DATE: 08/20/15 REVISED DATE: 10/20/16, 11/16/17
MEDICAL POLICY SUBJECT: PERCUTANEOUS LEFT ATRIAL CATEGORY: Technology assessment PAGE: 1 OF: 8 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply.
More informationRate or Rhythm Control? Epidemiology. Relevant Advances in Atrial Fibrillation 6/20/2011. Stroke Prophylaxis
Relevant Advances in Atrial Fibrillation Stroke Prophylaxis Managing Atrial Fibrillation: Tips for the Generalist Antiarrhythmic Drug Therapy Ablation Gregory M Marcus, MD, MAS Assistant Professor of Medicine
More informationMEDICAL POLICY MEDICAL POLICY DETAILS POLICY STATEMENT POLICY GUIDELINES DESCRIPTION. Page: 1 of 9
Page: 1 of 9 MEDICAL POLICY MEDICAL POLICY DETAILS Medical Policy Title PERCUTANEOUS LEFT ATRIAL APPENDAGE CLOSURE DEVICES Policy Number 7.01.92 Category Technology assessment Effective Date 08/20/15 Revised
More informationLeft atrium appendage closure: A new technique for patients at high hemorrhagic risk
Left atrium appendage closure: A new technique for patients at high hemorrhagic risk Victoria Martin Yuste MD PhD ITC. Cardiology Department. Hospital Clinic. Barcelona SITE. Barcelona, Juin-9-2013 NON
More informationLeft Atrial Appendage Closure: Neurological events
Left Atrial Appendage Closure: Neurological events Medical Director- Foundation for Cardiovascular Medicine San Diego, CA Director Advanced Interventional Therapies- Gagnon Cardiovascular Institute, Morristown,
More informationService Line: Rapid Response Service Version: 1.0 Publication Date: January 21, 2019 Report Length: 5 Pages
CADTH RAPID RESPONSE REPORT: REFERENCE LIST Topical Cantharidin/ Salicylic Acid/ Podophyllin for the Treatment of Warts: Clinical Effectiveness and Guidelines Service Line: Rapid Response Service Version:
More informationTITLE: Cognitive Behavioural Therapy for Insomnia in Adults: A Review of the Clinical Effectiveness
TITLE: Cognitive Behavioural Therapy for Insomnia in Adults: A Review of the Clinical Effectiveness DATE: 11 May 2010 CONTEXT AND POLICY ISSUES: Insomnia refers to difficulty initiating and/or maintaining
More informationWhat the general cardiologist should know about arrhythmia Stroke prevention in AF" Peter Ammann Kantonsspital St. Gallen
What the general cardiologist should know about arrhythmia Stroke prevention in AF" Peter Ammann Kantonsspital St. Gallen What the cardiologist should know about arrhythmia and stroke are there real low
More informationICE 2012 Ioannina,
ICE 2012 Ioannina, 15-12-2012 Case presentation Left Atrial Appendage Occlusion therapy for Stroke Prevention in Atrial Fibrillation Apostolos Tzikas MD, PhD, FESC Interventional Cardiology Congenital
More informationExclusion de l auricule gauche par voie percutanée
Exclusion de l auricule gauche par voie percutanée Jean-Michel Juliard, Dominique Himbert, Pierre Aubry, Eric Brochet, Alec Vahanian Hôpital Bichat, Paris Pas de conflit d intérêt 2012 The Left Atrial
More informationAtrial fibrillation (AF), one of the
Hellenic J Cardiol 2013; 54: 408-412 Case Report Left Atrial Appendage Occlusion with the Amplatzer Amulet for Stroke Prevention in Atrial Fibrillation: The First Case in Greece Apostolos Tzikas, Lambros
More informationUpdate in the Management of Atrial Fibrillation
Update in the Management of Atrial Fibrillation Gregory M Marcus, MD, MAS Associate Professor of Medicine Division of Cardiology University of California, San Francisco Disclosures Research: Gilead, Medtronic,
More informationService Line: Rapid Response Service Version: 1.0 Publication Date: March 5, 2018 Report Length: 5 Pages
CADTH RAPID RESPONSE REPORT: REFERENCE LIST Oral Neomycin in Preparation for Colorectal Procedures: Clinical Effectiveness, Cost- Effectiveness and Guidelines Service Line: Rapid Response Service Version:
More informationAbstract 1 INTRODUCTION ORIGINAL ARTICLE
Received: 5 October 2017 Revised: 2 November 2017 Accepted: 6 November 2017 DOI: 10.1111/jce.13385 ORIGINAL ARTICLE Feasibility of percutaneous left atrial appendage closure using a novel LAmbre occluder
More informationTITLE: Vitamin D Supplementation in the Elderly and Long-Term Care Residents: Clinical Effectiveness and Guidelines for Use
TITLE: Vitamin D Supplementation in the Elderly and Long-Term Care Residents: Clinical Effectiveness and Guidelines for Use DATE: 20 March 2009 RESEARCH QUESTIONS: 1. What is the clinical effectiveness
More informationManuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de
When not to exclude the LAA Manuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de Barcelona mcaste@clinic.ub.es @mcastellamd Normal hearts Patient in sinus rhythm Patient in AF (with
More informationIs there a role for transcatheter left atrial appendage occlusion?
REVIEW Review Is there a role for transcatheter left atrial appendage occlusion? For patients with atrial fibrillation, successful warfarin therapy is difficult in clinical practice. Thus, it seems logical
More informationUpdate in Left Atrial Appendage Closure Devices. Faisal Al-Samadi MBBS, FRCPC, FACP, FACC, FSCAI, FHRS
Update in Left Atrial Appendage Closure Devices Faisal Al-Samadi MBBS, FRCPC, FACP, FACC, FSCAI, FHRS Atrial Fibrillation - Overview Higher stroke risk for older patients and those with prior stroke or
More information1. What is the comparative efficacy of IV lorazepam and IV diazepam for the treatment of febrile seizures in children (less than 12 years of age)?
Title: The Use of Lorazepam for Febrile Seizures in Children Date: 25 January 2008 Context and policy issues: Febrile seizures are the most common form of childhood seizures, affecting approximately 2
More informationChapter 76 Left Atrial Appendage Closure: Indication and Technique
Chapter 76 Left Atrial Appendage Closure: Indication and Technique RANJAN SHETTY INTRODUCTION Atrial fibrillation (AF) is one of the most common cardiac arrhythmias, which affects around 3% 5% of the population
More informationThe Clinical Impact of Incomplete Left Atrial Appendage Closure With the Watchman Device in Patients With Atrial Fibrillation
Journal of the American College of Cardiology Vol. 59, No. 10, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.11.028
More informationTITLE: Shilla and MAGEC Systems for Growing Children with Scoliosis: A Review of the Clinical Benefits and Cost-Effectiveness
TITLE: Shilla and MAGEC Systems for Growing Children with Scoliosis: A Review of the Clinical Benefits and Cost-Effectiveness DATE: 17 January 2013 CONTEXT AND POLICY ISSUES Early-onset scoliosis (EOS)
More informationTITLE: Fluoridated Water for Cavity Prevention: Clinical and Cost-Effectiveness and
TITLE: Fluoridated Water for Cavity Prevention: Clinical and Cost-Effectiveness and Guidelines DATE: 29 April 2009 RESEARCH QUESTIONS: 1. What is the evidence for the clinical benefit and safety of fluoridated
More informationDepartment of Neurology, Medical University of Silesia, Hospital No. 7, Professor Leszek Giec Upper Silesian Medical Centre, Katowice, Poland
Original paper Percutaneous closure of the left atrial appendage for secondary prevention of stroke in patients with atrial fibrillation and contraindications to chronic anticoagulant therapy Anetta Lasek-Bal
More informationService Line: Rapid Response Service Version: 1.0 Publication Date: October 30, 2018 Report Length: 7 Pages
CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL Topical Silver Nitrate for the Management of Hemostasis: A Review of Clinical Effectiveness, Cost- Effectiveness, and Guidelines Service Line:
More informationLAA Occluders: The Right Device for the Right Patient ACC/SHA MEETING OCTOBER 31 ST 2015 JEDDAH, KSA OMER A. M. ELAMIN, MD, FACC
LAA Occluders: The Right Device for the Right Patient ACC/SHA MEETING OCTOBER 31 ST 2015 JEDDAH, KSA OMER A. M. ELAMIN, MD, FACC INTERVENTIONAL CARDIOLOGIST DIRECTOR, ADULT CARDIOLOGY FELLOWSHIP TRAINING
More informationListen to Your Heart. What Everyone Needs To Know About Atrial Fibrillation & Stroke. The S-ICD System. The protection you need
Listen to Your Heart The S-ICD System What Everyone Needs To Know About Atrial Fibrillation & Stroke The protection you need without Stroke. touching Are you your at heart risk? Increase your knowledge.
More informationTREATMENT OF STROKE PATIENTS THAT ARE TAKING NOVEL ANTICOAGULANTS. Jesse Weinberger, MD The Icahn School of Medicine at Mount Sinai
TREATMENT OF STROKE PATIENTS THAT ARE TAKING NOVEL ANTICOAGULANTS Jesse Weinberger, MD The Icahn School of Medicine at Mount Sinai Acknowledgement Many of the slides for this presentation were obtained
More informationUpdate in Left Atrial Appendage Occlusion: More Options
Update in Left Atrial Appendage Occlusion: More Options Sajjad A Sabir, MD Director, Structural Heart Disease Program Director, Interventional Echocardiography Director, Heart Valve Clinic Non-Valvular
More informationTITLE: Crushed Buprenorphine or Buprenorphine-Naloxone for Opioid Dependency: A Review of the Clinical Effectiveness and Guidelines
TITLE: Crushed Buprenorphine or Buprenorphine-Naloxone for Opioid Dependency: A Review of the Clinical Effectiveness and Guidelines DATE: 18 July 2016 CONTEXT AND POLICY ISSUES Opioid dependence is a chronic
More informationAMPLATZER Left Atrial Appendage Occluder. A Patient s Guide to the Non-surgical Closure of the Left Atrial Appendage
AMPLATZER Left Atrial Appendage Occluder A Patient s Guide to the Non-surgical Closure of the Left Atrial Appendage This brochure is intended to provide you with general information about the non-surgical
More informationAtrial fibrillation patient decision aid: Antithrombotic therapy
Atrial fibrillation patient decision aid: Antithrombotic therapy What this decision aid is for This decision aid is intended to assist health professionals in consultations with patients with atrial fibrillation
More information